Non-Eosinophilic Neutrophilic Asthma
[content_box icon=”bookmark-o” title=”Research team”]
Dr. Vicente Plaza Moral (PRINCIPAL INVESTIGATOR)
Hospital de la Santa Creu I Sant Pau (HSP)
Dra. Astrid Crespo Lessmann
Hospital de la Santa Creu I Sant Pau
Dra. Ana Lapuente Torrents
Hospital Mutua de Terrassa
Dr. Eder Mateus Medina
Institut de Recerca IIB Sant Pau
Dra. Elena Curto Sánchez
Hospital de la Santa Creu I Sant Pau
Dr. Jordi Giner Donaire
Hospital de la Santa Creu I Sant Pau
Dr. David Ramos Barbón
Hospital de la Santa Creu I Sant Pau
Dra. Silvia Vidal Alcorisa
Institut de Recerca IIB Sant Pau
Dr. Xavier Muñoz Gall
Hospital Universitari Vall d’Hebron
Dra. Mariana Mercedes Muñoz
Esquerre
Hospital Universitari de Bellvitge
Dr. Carles Sabadell Nieto
Hospital de Figueres/ Fundació Salut Empordà
Dra. Concepción Cañete Ramos
Hospital General de l’Hospitalet/Consorci Sanitari
Integral
Dra. Benedicta Abeijon Insua
Hospital de Terrassa/Consorci Sanitari de Terrassa
Dra. Pilar Ausin Herrero
Hospital del Mar/Consorci Parc de Salut Mar
Dr. Joan Serra Batlles
Hospital Universitari de Vic/Consorci Hospitalari de
Vic
Dra. Ebymar Arismendi
Hospital Universitari Clínic de Barcelona
Dr. Cesar Picado Vallés
Hospital Universitari Clínic de Barcelona
Dra. Rosa Mª del Campo Moreno
Instituto Ramón y Cajal de Investigación Sanitaria
Dr. Gustavo Rodrigo
Hospital Central de las Fuerzas Armadas de
Montevideo (Uruguay)
[/content_box]
[content_box icon=”bookmark-o” title=”Abstract”]
Neutrophilic asthma (NA) is the least known phenotype of asthma, causes severe illness and has no specific treatment. Research on neutrophilic mechanisms, new types of neutrophils (NEU) and bronchial microbioma can offer an opportunity for a better understanding of their pathogenesis.
OBJECTIVES: 1. To describe the clinical characteristics of the NA and its subtypes (substudy 1); 2. To characterize the NEUs associated with it and its subtypes (substudy 2); and 3. To identify its bronchial microbial flora, in particular its association with the immune response to Chlamydia Pneumoniae (substudy 3).
METHODS: prospective multicentric study involving 100 patients with severe asthma (GEMA/GINA criteria): 50 with non-neutrophilic asthma (<65% NEU in induced sputum (IS) and 50 with NA (>64% NEU in IS).
Substudy 1: clinical variables will be collected (evolution years, exacerbations, ACT, miniAQLQ), comorbidities (RGE, nasal polyposis, obesity, SAHS), pulmonary function (FEV1, FENO, TLC, VR, KCO), blood analysis (leukocyte formula, IgE, IgG Aspergillus), prick-test and thorax CT.
Substudy 2 (in IS and plasma): apoptotic index by culture of NEU and flow cytometry (Annexin-V-FITC), NEU phenotype by surface markers (CD177, CD16, CD66b, CD62L, CD11b, CD63, HLA-DR, CXCR2, CXCR4) with density gradient study and cytokine determination (IL-6 IL-8, IL-1, IL-22, IL-17) by ELISA.
Substudy 3: (in IS and plasma): bronchial microbioma by 16S rRNa PICRUSt and anti-Chlamydia Pneumoniae IgA by ELISA.
[/content_box]